ArticleDiabetes2013
Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist exendin-4.
Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study.Journal of diabetes research · 2019Trial
- Diet-induced obesity impairs refeeding responses and downregulates lateral septal GLP-1R in male rats: an effect reversed by weight-loss treatment.Frontiers in pharmacology · 2026Article
- Reduced liver mitochondrial energy metabolism impairs food intake regulation following gastric preloads and fasting.Molecular metabolism · 2025Article
- Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.Comprehensive Physiology · 2025Review
- Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease.Frontiers in endocrinology · 2024Review
- Glucagon-Like Peptide-1 Receptors in the Gustatory Cortex Influence Food Intake.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.Frontiers in pharmacology · 2023Article
- Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.Translational psychiatry · 2022Article
- GLP-1 physiology informs the pharmacotherapy of obesity.Molecular metabolism · 2022Review
- Gastrointestinal peptides in eating-related disorders.Physiology & behavior · 2021 · on this mapReview
- The metabolic impact of small intestinal nutrient sensing.Nature communications · 2021Review
- Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease.Cell & bioscience · 2020Review
- Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs.BMJ open diabetes research & care · 2020Article
- High-fat diet alters fluid intake without reducing sensitivity to glucagon-like peptide-1 receptor agonist effects.Physiology & behavior · 2020Article
- Glucagon-Like Peptide-1 Secreting L-Cells Coupled to Sensory Nerves Translate Microbial Signals to the Host Rat Nervous System.Frontiers in cellular neuroscience · 2020Article
- Role of astroglia in diet-induced central neuroplasticity.Journal of neurophysiology · 2019Review
- The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity.Obesity science & practice · 2017Article
- Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Physiological reviews · 2017Review
- Inhibitory neurotransmission regulates vagal efferent activity and gastric motility.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.Cellular and molecular life sciences : CMLS · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal mechanisms involved in the suppression of appetite are compromised in obesity. Glucagon-like peptide-1 (GLP-1) is released in response to nutrients, suppresses food intake, and has been shown to play a role in regulation of energy balance. It is not known whether obese-prone (OP) rats exhibit dysfunctional GLP-1 signaling that could contribute to decreased nutrient-induced satiation and hyperphagia. Therefore, we examined the effects of exogenous intraperitoneal administration of the GLP-1R agonist, exendin-4 (Ex-4), on food intake in OP and obese-resistant (OR) rats during chow or high-energy/high-fat (HE/HF) feeding. All doses of Ex-4 effectively suppressed intake in OP and OR rats fed chow; however, during HE/HF-feeding, OP rats suppressed intake significantly less than OR rats at all Ex-4 doses tested. This was associated with downregulation of GLP-1R mRNA expression in the vagal nodose ganglia of OP rats. Furthermore, HE/HF-fed OP rats had significantly lower plasma GLP-1 levels, decreased protein levels of GLP-1 in the intestinal epithelium, and reduced number of L cells in the distal ileum. These results demonstrate that HE/HF-feeding, coupled with OP phenotype, results in reduced endogenous GLP-1 and GLP-1R activation, indicating that impaired GLP-1 signaling during obesity may exacerbate hyperphagia and weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.